Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14740/jocmr2477w http://scihub22266oqcxt.onion/10.14740/jocmr2477w C4780498!4780498!26985255     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Med+Res 2016 ; 8 (4): 334-7 Nephropedia Template TP {{tp|p=26985255|t=2016. Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet?s Disease: Eight Consecutive Cases |pdf=|usr=}}{{26985255}} gab.com Text Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet s Disease: Eight Consecutive Cases JO: J Clin Med Res http://www.kidney.de/pget.php?&tw=1&pmid=26985255 #FOAvip The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet?s disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conventional therapy were given ADA (160/80/40 mg every other week). Marked improvement (MI) was achieved by 10 weeks in five patients (62.5%), and by 52 weeks in six patients (75%). In addition, complete remission was obtained in two patients (25%) at both 10 and 52 weeks. Improvement of global gastrointestinal (GI) symptoms to score 0 was observed in three patients (37.5%) at 10 weeks and four patients (50%) at 52 weeks. Moreover, improvement of endoscopic assessment to score 0 was also seen in four patients (50%) at both 10 and 52 weeks. No adverse events were observed in any patients during the 52 weeks. In conclusion, ADA offers an effective, well-tolerated treatment for intestinal BD in patients who are refractory to conventional therapy. Twit Text FOAVip Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet s Disease: Eight Consecutive Cases ????J Clin Med Res http://www.kidney.de/pget.php?&tw=1&pmid=26985255 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26985255 #FOAvip English Wikipedia <ref>{{Cite pmid|26985255}}</ref> Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet?s Disease: Eight Consecutive Cases #MMPMID26985255 Tanida S; Mizoshita T; Nishie H; Ozeki K; Katano T; Shimura T; Kubota E; Kataoka H; Kamiya T; Joh T J Clin Med Res 2016[Apr]; 8 (4): 334-7 PMID26985255show ga The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet?s disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conventional therapy were given ADA (160/80/40 mg every other week). Marked improvement (MI) was achieved by 10 weeks in five patients (62.5%), and by 52 weeks in six patients (75%). In addition, complete remission was obtained in two patients (25%) at both 10 and 52 weeks. Improvement of global gastrointestinal (GI) symptoms to score 0 was observed in three patients (37.5%) at 10 weeks and four patients (50%) at 52 weeks. Moreover, improvement of endoscopic assessment to score 0 was also seen in four patients (50%) at both 10 and 52 weeks. No adverse events were observed in any patients during the 52 weeks. In conclusion, ADA offers an effective, well-tolerated treatment for intestinal BD in patients who are refractory to conventional therapy. äLong-Term Efficacy of Adalimumab in Patients With Intestinal Behcet?s (epmc).pdf DeepDyve Pubget Overpricing